CGEM stock icon

Cullinan Oncology
CGEM

$21.71
6.97%
 

About: Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Employees: 85

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 10 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

157% more call options, than puts

Call options by funds: $215K | Put options by funds: $83.5K

79% more capital invested

Capital invested by funds: $376M [Q4 2023] → $671M (+$295M) [Q1 2024]

11% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 37

5.26% more ownership

Funds ownership: 86.16% [Q4 2023] → 91.42% (+5.26%) [Q1 2024]

0% more funds holding

Funds holding: 113 [Q4 2023] → 113 (+0) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 19

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$26
20%
upside
Avg. target
$31
42%
upside
High target
$40
84%
upside

10 analyst ratings

10 positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Edward White
29%upside
$28
Buy
Reiterated
3 Jun 2024
HC Wainwright & Co.
Edward White
29%upside
$28
Buy
Reiterated
24 May 2024
HC Wainwright & Co.
Edward White
29%upside
$28
Buy
Maintained
16 May 2024
Wedbush
Robert Driscoll
66%upside
$36
Outperform
Reiterated
16 May 2024
Stifel
Bradley Canino
84%upside
$40
Buy
Initiated
1 May 2024

Financial journalist opinion

Based on 4 articles about CGEM published over the past 30 days